CEO Statement to Shareholders

OSR Holdings (OSRH) issued a CEO statement on May 12, 2026, confirming it will not pursue a reverse stock split to regain Nasdaq minimum bid compliance.

Rhea-AI Summary

OSR Holdings (OSRH) issued a CEO statement on May 12, 2026, confirming it will not pursue a reverse stock split to regain Nasdaq minimum bid compliance. Management plans to restore compliance through operational execution and milestones, not structural actions.

According to OSR Holdings, the company signed definitive agreements with BCM Europe AG for a global exclusive license of oncology asset VXM01, with up to $815 million in potential milestone payments. Subsidiary Woori IO continues its non-invasive glucose monitoring collaboration with Samsung Electronics and NDA-protected discussions with Sinopharm.

Positive

• VXM01 global license with BCM Europe AG, up to $815 million milestones
• No reverse stock split, avoiding immediate structural share change for investors
• Focus on organic recovery to restore Nasdaq bid compliance via execution
• Woori IO development with Samsung collaboration and Sinopharm NDA discussions

Negative

• Nasdaq minimum bid compliance remains unresolved and timing is uncertain
• No structural options like a reverse split retained as a contingency tool

Argus May 12 session

+13.09% close to close Open Argus

Details

News Market Reaction – OSRH

In the May 12 session, OSRH gained 13.09%, reflecting a significant positive market reaction.

Data tracked by StockTitan Argus on the day of publication.

Market Context

The stock surged +13.1% in the session following this news. A strong positive reaction aligns with m...

Analysis

The stock surged +13.1% in the session following this news. A strong positive reaction aligns with management’s clear stance against a reverse stock split and emphasis on “organic” Nasdaq compliance. Investors have previously reacted sharply to VXM01 and capital-structure news, with both rallies and selloffs on major announcements. Any outsized upside move could be tempered if enthusiasm fades around execution risks or if prior volatility patterns re-emerge. Monitoring delivery on VXM01 milestones and the Woori IO platform would remain central for sustaining gains.

Key Figures

VXM01 milestone potential: $815 million VXM01 agreement date: April 29, 2026 PRE 14A filing date: May 11, 2026 +1 more

VXM01 milestone potential

$815 million

Potential milestone payments under BCM Europe AG global license

VXM01 agreement date

April 29, 2026

Date OSR Holdings executed definitive VXM01 license agreements

PRE 14A filing date

May 11, 2026

Date Preliminary Proxy Statement on Schedule PRE 14A was filed

CEO statement date

May 12, 2026

Date of CEO letter committing to no reverse stock split

Historical Context

5 past events · Latest: May 05

5 events

1. May 05

   Analyst flash report

   24h Move

   -10.8%

   Research note reaffirming bullish view after VXM01 license and financing structure.

2. Apr 30

   Conference presentation

   24h Move

   +52.8%

   Announcement of VXM01 licensing presentation and live Q&A at growth conference.

3. Apr 29

   VXM01 license deal

   24h Move

   -38.2%

   Definitive global license for VXM01 with large milestone potential and IP transfer.

4. Apr 09

   Capital structure move

   24h Move

   +3.8%

   Convertible note to retire warrant overhang and support Nasdaq bid compliance.

5. Mar 30

   Investor update

   24h Move

   +13.8%

   Emerging Growth Conference update on VXM01 and Woori IO glucose platform.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Key Terms

reverse stock split, schedule pre 14a, preliminary proxy statement, nasdaq minimum bid requirement, +1 more

5 terms

reverse stock split financial

"Notably, the PRE 14A did not include a proposal authorizing a reverse stock split."

A reverse stock split reduces a company's number of outstanding shares while raising the price per share proportionally, so the total value of each investor's holding is unchanged; a 1-for-10 split turns 100 shares worth $1 each into 10 shares worth $10 each. Companies often do this to regain compliance with an exchange's minimum price rule or to attract investors who avoid very low-priced stocks.

schedule pre 14a regulatory

"OSR Holdings filed its Preliminary Proxy Statement on Schedule PRE 14A with the U.S."

A Schedule PRE 14A is a preliminary proxy filing companies submit to the U.S. Securities and Exchange Commission before sending final voting materials to shareholders. Think of it as a draft of the packet shareholders will use to vote on matters like board members, executive pay, or takeover proposals; it gives investors an early, legally required look at the issues and arguments before the official vote. Investors watch these filings because they reveal planned corporate actions and can signal contested votes or governance changes that may affect a company’s value.

preliminary proxy statement regulatory

"OSR Holdings filed its Preliminary Proxy Statement on Schedule PRE 14A with the U.S."

A preliminary proxy statement is an advance draft of the information a company will send shareholders before a vote, outlining items like board elections, mergers, executive pay, and shareholder proposals. It matters to investors because it lays out what will be decided, management’s recommendations, and key facts that can affect a company’s direction and stock value — like receiving the agenda and background packet before a town-hall vote.

nasdaq minimum bid requirement regulatory

"Management remains fully committed to restoring compliance with Nasdaq's minimum bid requirement"

A Nasdaq minimum bid requirement is the rule that a stock’s share price must stay above a set minimum level (usually $1) to remain listed on the Nasdaq exchange. It matters to investors because falling below that threshold can trigger a warning and potential delisting, similar to a store losing its license if it fails health inspections; delisting can reduce liquidity, limit who can trade the stock, and often lowers its market value.

non-invasive glucose monitoring medical

"Woori IO continues to advance its non-invasive glucose monitoring platform through its collaboration"

A method of measuring a person’s blood sugar level without drawing blood or puncturing the skin, using external sensors or signals to estimate glucose much like a thermometer reads temperature without opening the body. It matters to investors because successful non-invasive systems could replace disposable test strips and finger pricks, opening a large consumer and clinical market and creating ongoing device, software and service revenue — though commercial value depends on accuracy and regulatory approval.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

A Clear Commitment: No Reverse Stock Split

BELLEVUE, WA / ACCESS Newswire / May 12, 2026 / As many of our shareholders are aware, OSR Holdings filed its Preliminary Proxy Statement on Schedule PRE 14A with the U.S. Securities and Exchange Commission on May 11, 2026. Given the proximity of our Nasdaq minimum bid compliance deadline, we believe it is important to provide direct and unambiguous transparency regarding our strategy.

Notably, the PRE 14A did not include a proposal authorizing a reverse stock split.

This was a deliberate decision, and it reflects our firm conviction.

We will not pursue a reverse stock split.

Management has evaluated this path and rejected it. We believe reverse splits do not create shareholder value. They are structural maneuvers that leave business fundamentals unchanged. We intend to earn our Nasdaq minimum bid compliance back through organic execution, not financial engineering.

Committed to Organic Recovery Driven by Subsidiary Milestones

On April 29, 2026, OSR Holdings executed definitive agreements with BCM Europe AG for the global exclusive license of VXM01, representing up to $815 million in potential milestone payments and marking a major milestone for our oncology platform.

In parallel, Woori IO continues to advance its non-invasive glucose monitoring platform through its collaboration with Samsung Electronics, while also progressing discussions under NDA with Sinopharm.

These are the kinds of developments that build real, durable shareholder value. We intend to continue delivering on them.

Our Position Is Clear

Management is focused entirely on restoring shareholder value through operational execution and strategic milestone delivery. We believe this is the right path forward for our shareholders, for our business, and for the long-term credibility of OSR Holdings as a public company.

There will be no reverse split. We believe the market will come to reflect the fundamental value we are building.

Commitment to Nasdaq Compliance Through Execution

Management remains fully committed to restoring compliance with Nasdaq's minimum bid requirement through the continued delivery of meaningful corporate milestones and disciplined engagement with the investment community - not through structural actions that do not improve our business fundamentals.

While there can be no assurance regarding timing or outcomes, we remain fully engaged with our advisors and Nasdaq as we work toward restoring compliance on our own terms.

We appreciate the continued support of our shareholders and remain confident in the long-term opportunities ahead for OSR Holdings.

Sincerely,

Kuk Hyoun "Peter" Hwang
Chief Executive Officer
OSR Holdings, Inc.

About OSR Holdings, Inc.

OSR Holdings, Inc. (NASDAQ:OSRH) is a global healthcare holding company dedicated to advancing biomedical innovations in health and wellness. Through its subsidiaries, OSR Holdings engages in immuno-oncology, regenerative biologics, and medical device technologies to improve health outcomes worldwide. Learn more at www.OSR-Holdings.com.

Investor Contact

OSR Holdings, Inc.
Investor Relations
ir@osr-holdings.com

Forward Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including statements regarding Nasdaq compliance, strategic transactions, commercialization initiatives, and future business developments. Forward-looking statements are based on current expectations and assumptions and are subject to risks and uncertainties that could cause actual results to differ materially. Readers are cautioned not to place undue reliance on these forward-looking statements. OSR Holdings undertakes no obligation to update these statements except as required by law.

SOURCE: OSR Holdings, Inc.

View the original press release on ACCESS Newswire

FAQ

Why did OSR Holdings (OSRH) rule out a reverse stock split in May 2026?

OSR Holdings ruled out a reverse stock split because management believes it does not create shareholder value. According to OSR Holdings, reverse splits are structural and leave fundamentals unchanged, so the company aims to regain Nasdaq compliance through business execution instead.

What is the value of the VXM01 license deal OSR Holdings (OSRH) announced in 2026?

The VXM01 license deal carries up to $815 million in potential milestone payments. According to OSR Holdings, definitive agreements with BCM Europe AG grant a global exclusive license, representing a major milestone for the company’s oncology platform and long-term value strategy.

How does OSR Holdings (OSRH) plan to regain Nasdaq minimum bid compliance without a reverse split?

OSR Holdings plans to restore Nasdaq minimum bid compliance through organic execution and corporate milestones. According to OSR Holdings, management will focus on advancing programs like VXM01, Woori IO’s glucose monitoring platform, and disciplined engagement with investors, while acknowledging timing and outcomes are uncertain.

What role does Woori IO play in OSR Holdings (OSRH) 2026 strategy?

Woori IO is central to OSR Holdings’ strategy through its non-invasive glucose monitoring platform. According to OSR Holdings, Woori IO is collaborating with Samsung Electronics and holding NDA-governed discussions with Sinopharm, which management views as contributors to building durable shareholder value.

How significant is the BCM Europe AG partnership for OSR Holdings (OSRH) oncology platform?

The BCM Europe AG partnership is described as a major milestone for OSR Holdings’ oncology platform. According to OSR Holdings, the VXM01 global exclusive license, with up to $815 million in milestones, underpins the company’s commitment to value creation through strategic asset development.

What message did the OSR Holdings (OSRH) CEO send to shareholders on May 12, 2026?

The CEO emphasized a clear commitment to value creation without a reverse stock split. According to OSR Holdings, management will prioritize operational execution, milestone delivery, and constructive investor engagement to rebuild shareholder value and work toward Nasdaq bid compliance on the company’s own terms.